The global clinical trial supply and logistics market size is expected to surpass around US$ 12.4 billion by 2030 from valued at US$ 5.1 billion in 2020 with a CAGR of 9.1% from 2021 to 2030.
The global clinical trial supply and logistics market size is expected to surpass around US$ 12.4 billion by 2030 from valued at US$ 5.1 billion in 2020 with a CAGR of 9.1% from 2021 to 2030.
Growth Factors
The market growth is attributed to the increasing R&D expenditure by pharmaceutical and biopharmaceutical firms and the rising number of clinical trials conducted globally. Furthermore, the market is mostly driven by technological advancements in the supply chain. The growing complexity in clinical studies and increased competition among players are factors responsible for the adoption of new technologies in supply chain management.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38699
clinical trials have increased due to the rising demand for the Covid-19 vaccine. According to the WHO, more than 80 vaccines are currently being studied in clinical trials, with over 180 in the pre-clinical stage. There would be a challenge for logistics related to timelines and access to a large population.
By Service Analysis
The logistics and distribution segment led the market and accounted for a revenue share of over 20.0% in 2020. The segment is also anticipated to register the fastest growth rate throughout the forecast period. This is due to the globalization of clinical trials, an increase in the number of trials involving temperature-sensitive products, and the highly regulated structure of the industry.
Technological developments are positively impacting the global market, both on the inbound and outbound sides. As additional Point of Care (POC) diagnostic tools are developed, there would be a trend toward performing more and more local analyses and transferring less blood, tissue, urine, and other samples to a central site for examination in the future.
Advances in smart packaging solutions, such as active and passive thermo-regulated products, ensure that shipments stay within suitable temperature ranges while en-route and in storage, protecting the contents of the shipment.
Report Coverage
| Report Scope | Details |
| Market Size | USD 12.4 billion by 2030 |
| Growth Rate | CAGR of 9.1% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Service, Phase, End-user, Therapeutic area |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Thermo Fisher Scientific (U.S.) (Patheon); Catalent, Inc. (U.S.); Parexel (U.S.); Almac Group; Marken; Piramal Pharma Solutions; UDG Healthcare; DHL; FedEx; Movianto; Packaging Coordinators Inc. |
By Phase Analysis
The phase III segment held the largest revenue share of over 40.0% in 2020. This is primarily due to a rise in the number of patients enrolled in phase III trials. Investigators in phase III studies compare the novel treatment’s safety and efficacy against the current standard of care.
Phase II clinical trials had the highest number of projects in 2020 and this trend is expected to continue owing to increasing investments in R&D by industry and non-industry sponsors.
Ask here for more details@ https://www.visionresearchreports.com/report/enquiry/38699
By Therapeutic Area Analysis
The cardiovascular diseases segment led the largest revenue share of over 25.0% in 2020. This is due to the large and growing number of cardiovascular research studies and the growing number of companies focused on bringing innovative drugs to the market.
The oncology segment held the second-largest share in 2020. This is due to the high prevalence of cancer. In 2018, cancer was the second biggest cause of death around the world, accounting for 9.6 million fatalities, or one in every six deaths.
By End-user Analysis
Based on end-user, the pharmaceuticals segment led the market and accounted for over 40.0% share in 2020. This is due to the increased number of clinical studies conducted by pharmaceutical companies and R&D investments by these companies. Besides, the globalization of clinical trials is supporting market growth.
The biologicals segment is projected to expand at the fastest growth rate of 7.3% over the forecast period. This may be largely attributed to the increasing demand for biological products, such as cell and gene therapies, and vaccines and the growing investments in product development
By Regional Analysis
North America held the global market with a share of over 35.0% in 2020. An increase in the number of clinical trials conducted by pharmaceutical companies drives the market in the region. According to ClinicalTrials.gov, the U.S. performs the highest number of clinical trial operations per year.
Asia Pacific is anticipated to register the fastest growth rate of7.8% throughout the forecast period. The region has access to a large and diversified patient pool, cheaper recruitment costs, and favorable policies that make Asia Pacific desirable for clinical studies.
Key Players
- Piramal Pharma Solutions
- UDG Healthcare
- DHL
- FedEx
- Movianto
- Packaging Coordinators Inc.
- Thermo Fisher Scientific (Patheon)
- Catalent, Inc.
- Parexel
- Almac Group
- Marken
Market Segmentation
- Service
- Logistics & Distribution
- Storage & Retention
- Packaging, Labeling, and Blinding
- Manufacturing
- Comparator Sourcing
- Other Services (Solutions, Ancillary Supply)
- Phase
- Phase I
- Phase II
- Phase III
- Phase IV
- End-user
- Pharmaceuticals
- Biologicals
- Medical Device
- Therapeutic Area
- Oncology
- Cardiovascular Diseases
- Respiratory Diseases
- CNS and Mental Disorders
- Others
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@https://www.visionresearchreports.com/report/cart/38699
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333